STOCK TITAN

BioRestorative Therapies Inc - BRTX STOCK NEWS

Welcome to our dedicated news page for BioRestorative Therapies (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioRestorative Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioRestorative Therapies's position in the market.

Rhea-AI Summary
BioRestorative Therapies (BRTX) is advancing its lead candidate, BRTX-100, a cell-based therapy for chronic lumbar disc disease. The recent data presented at the ORS 2024 Annual Meeting showed positive trends in pain and function improvements. The therapy uses autologous stem cells manufactured in a low oxygen environment to mimic disc conditions. If successful, BRTX-100 could revolutionize disc-related pain treatment with its personalized, minimally invasive approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
Rhea-AI Summary
BioRestorative Therapies, Inc. announced agreements with certain holders of its existing warrants to exercise their warrants at a reduced price, generating approximately $8.1 million in gross proceeds. The reduction of the exercise price and issuance of new warrants was structured as an at-market transaction under Nasdaq rules. The new warrants will be exercisable into an aggregate of up to 2,513,685 shares of common stock, at an exercise price of $2.43 per share, and have a term of exercise equal to five years. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.49%
Tags
none
-
Rhea-AI Summary
BioRestorative Therapies, Inc. announced preliminary 26 and 52-week blinded data from the ongoing Phase 2 clinical trial of their lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease. The data presented at the Orthopaedic Research Society 2024 Annual Meeting showed positive trends in pain and function scales compared to baseline, indicating meaningful signals in patients enrolled in the study. The company also reported no notable safety signals, and the FDA will use the data to determine whether the trial will be allowed to proceed and ultimately gain Biologics License Application (BLA) approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.21%
Tags
clinical trial
Rhea-AI Summary
BioRestorative Therapies, Inc. announced preliminary blinded data from the ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease. The data will be presented at the Orthopaedic Research Society 2024 Annual Meeting. BRTX-100 is a novel cell-based therapeutic evaluated for safety and efficacy in treating cLDD. The company will host a webcasted conference call to review the data on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.52%
Tags
conferences clinical trial
-
Rhea-AI Summary
BioRestorative Therapies, Inc. (BRTX) has been granted a notice of allowance for a U.S. patent related to the Company’s metabolic ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes. This will be the fourth U.S. patent granted under this particular patent family, covering methods of using differentiated human brown fat adipocytes to screen and identify compounds that can activate and regulate metabolic activity. The Company sees this as an important milestone, providing them with tools to screen large libraries of compounds targeting metabolic disorders such as obesity, potentially leading to the development of drugs targeting weight loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
none
-
Rhea-AI Summary
BioRestorative Therapies CEO to present at ROTH MKM Healthcare Opportunities Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
Rhea-AI Summary
BioRestorative Therapies strategically positions itself for future growth with expanding manufacturing capacity, increased demand for BRTX-100, and advancements in intellectual property. Roth MKM projects a stock price target of $15 over the next 12 months, compared to the current $2.59. The company had pro forma cash of $13.4 million and $3.3 million remaining in its at-the-market facility. BioRestorative received a unanimous recommendation to continue its Phase 2 trial for evaluating BRTX-100 in patients with chronic lumbar disc disease. The company has made efforts to ramp up manufacturing and quality control capacity and has obtained a license to serve as a tissue bank for processing mesenchymal stem cells. The global mesenchymal stem cell market is expected to grow at a CAGR of 12.8% from 2023 to 2030. BioRestorative can expand its clinical operations and has collaborated with Northwell Health for trial sites. Other companies in the space include Mesoblast, Brainstorm Cell Therapeutic, and Longeveron.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
none
-
Rhea-AI Summary
BioRestorative enters supply agreement with Evolutionary Biologics for cosmetic applications, representing initial venture into $62.8B global aesthetics market. Initial order of 5,000 vials will have positive financial impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.37%
Tags
none
-
Rhea-AI Summary
BioRestorative announces site activation for BRTX-100 trial in New York, allowing patient recruitment and enrollment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
clinical trial
Rhea-AI Summary
BioRestorative Therapies aims to provide better treatment options for chronic pain without the need for opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
none
BioRestorative Therapies Inc

Nasdaq:BRTX

BRTX Rankings

BRTX Stock Data

9.84M
3.55M
24.18%
13.81%
1.12%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Melville

About BRTX

biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas